SAB Biotherapeutics, Inc. (SABS)
3.71
-0.08
(-2.11%)
USD |
NASDAQ |
Aug 31, 16:00
3.715
0.00 (0.00%)
After-Hours: 20:00
SAB Biotherapeutics Shareholders Equity (Quarterly) : 214.78M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 214.78M |
| March 31, 2026 | 227.25M |
| December 31, 2025 | 151.49M |
| September 30, 2025 | 165.07M |
| June 30, 2025 | 12.02M |
| March 31, 2025 | 21.41M |
| December 31, 2024 | 25.97M |
| September 30, 2024 | 36.90M |
| June 30, 2024 | 46.12M |
| March 31, 2024 | 52.82M |
| December 31, 2023 | 57.30M |
| September 30, 2023 | 15.26M |
| Date | Value |
|---|---|
| June 30, 2023 | 19.72M |
| March 31, 2023 | 24.40M |
| December 31, 2022 | 31.06M |
| September 30, 2022 | 30.62M |
| June 30, 2022 | 37.12M |
| March 31, 2022 | 41.26M |
| December 31, 2021 | 38.55M |
| September 30, 2021 | 106.86M |
| June 30, 2021 | 107.19M |
| March 31, 2021 | 109.39M |
| December 31, 2020 | 0.016M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 238.21M |
| Total Liabilities (Quarterly) | 23.42M |
| Debt to Equity Ratio | 0.0239 |
| Current Ratio | 9.221 |
| Net Debt Paydown Yield | 0.10% |